Cite
HARVARD Citation
Wu, X. et al. (n.d.). 357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial. International journal of gynecological cancer. p. A147. [Online].